LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Suletud

Sektor Tervishoid

1.35 -1.46

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.33

Max

1.36

Põhinäitajad
By Trading Economics
Sissetulek	15M 614K
Müük	14M 56M
P/E Sektori keskmine	26.504 103.001
Aktsiakasum	-0.08
Kasumimarginaal	1.093
Töötajad	167
EBITDA	14M 11M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+362.96 upside

Turustatistika
By TradingEconomics
Turukapital	10M 322M
Eelmine avamishind	2.81
Eelmine sulgemishind	1.35

Uudiste sentiment

By Acuity

61%

39%

296 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

1.3 / 1.55 Toetus ja vastupanu

Akebia Therapeutics Inc Graafik

Seotud uudised

28. märts 2024, 10:30 UTC

Suurimad hinnamuutused turgudel

Akebia Shares Rally Premarket After FDA Approves Vafseo

Võrdlus sarnastega

Hinnamuutus

Akebia Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

362.96% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD 362.96%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Akebia Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Akebia Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.3 / 1.55Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

296 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Akebia Therapeutics Inc

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.